Generic version of a drug already on the market, which can suppress and prevent HIV, would still yield 30% profit if the current price was slashed, researchers say
A new drug described as “the closest we have ever been to an HIV vaccine” could cost $40 (£31) a year for every patient, a thousand times less than its current price, new research suggests.
Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.
About Author
More Stories
Male mosquitoes to be genetically engineered to poison females with semen in Australian research
Bizarre Australian mole even more unusual than first thought, new research reveals
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict